---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-006992"
form_type: "8-K"
ticker: "AMRN"
cik: "0000897448"
company_name: "AMARIN CORP PLCUK"
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:17:49.027425+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amarin achieves positive cash flow in Q4 2025 ahead of schedule; FY revenue $212-217M

## Summary
- Year-end cash $303M, up $16M from Q3; no debt; Q4 positive cash flow achieved earlier than forecast.
- Q4 2025 net revenue expected $48-53M; FY 2025 net revenue $212-217M.
- Restructuring: 50% of $70M OPEX savings realized; full benefit on track by June 30, 2026. Estimated restructuring costs raised to $37-40M.
- VASCEPA >50% IPE prescription share in US; Recordati now managing European commercialization in most launched countries.
- Two new regulatory approvals (South Korea and Singapore); >10 abstracts and >20 manuscripts published in 2025.

## SEC filing metadata
- accession: 0001193125-26-006992
- form_type: 8-K
- ticker: AMRN
- cik: 0000897448
- company_name: AMARIN CORP PLCUK
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/897448/000119312526006992/0001193125-26-006992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/897448/000119312526006992/amrn-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-006992
- JSON: https://secwatch.observer/filing/0001193125-26-006992.json
- Plain text: https://secwatch.observer/filing/0001193125-26-006992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.